Results 71 to 80 of about 53,817 (192)

Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer

, 2010
Noemí Reguart1, Andrés Felipe Cardona2, Rafael Rosell31Medical Oncology Service, ICMHO, Hospital Clinic Barcelona, Barcelona, Spain; 2Clinical and Translational Oncology Group, Institute of Oncology, Fundación Santa Fe de
Andrés Felipe Cardona, Noemí Reguart, Rafael Rosell   +2 more
core  

Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer

BMC Cancer, 2007
Background Erlotinib is a Human Epidermal Growth Factor Receptor Type 1/tyrosine kinase (EGFR) inhibitor which is used for non-small-cell lung cancer treatment.
Colin Guillaume, Copin Marie, Scherpereel Arnaud, Makris Demosthenes, Brun Luc, Lafitte Jean, Marquette Charles   +6 more
doaj   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, Volume 20, Issue 10, Page 2424-2448, October 2026.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Erlotinib-induced bullous pemphigoid

, 2012
Erlotinib binds to intracellular domain of the epidermal growth factor receptor (EGFR), causing several cutaneous and mucous membrane reactions. However no cases of erlotinib-induced bullous pemphigoid where previously reported.
STINGENI, LUCA, LISI, Paolo, BIANCHI, LEONARDO, Minotti, V.   +3 more
core   +1 more source

Molecular Mechanism of Erlotinib Resistance in Epidermal Growth Factor Receptor 
Mutant Non-small cell Lung Cancer Cell Line H1650

Chinese Journal of Lung Cancer, 2012
Background and objective Epidermal growth factor receptor (EGFR) overexpression and mutations were existed in more than 40% of the lung cancer, and it’s the one of molecular targets in clinical treatment.
Ruili HAN, Xiaoli WANG, Diansheng ZHONG, Juan ZHAO, Zhe CHEN, Linlin SUN, Jing WANG, Jinbang ZHANG   +7 more
doaj   +1 more source

Phase II trial of second-line erlotinib and digoxin for nonsmall cell lung cancer (NSCLC)

, 2011
Fadi Kayali, Muhamad A Janjua, Damian A Laber, Donald Miller, Goetz H KloeckerUniversity of Louisville, James Graham Brown Cancer Center, Louisville, KY, USABackground: In vitro digoxin sensitizes cancer cells to the induction of apoptosis by ...
Muhamad A Janjua, Donald Miller, Damian A Laber, Goetz H Kloecker, Fadi Kayali   +4 more
core  

Autophagy inhibition cooperates with erlotinib to induce glioblastoma cell death.

, 2011
International audienceGliomas are the most common malignant primary brain tumors in adults. The median survival never exceeds 12 months, owing to inherent resistance to both radio and chemotherapies.
Véron, Nadège, Jeanneteau, Marie, Belloc, Francis, Vital, Anne, Marc-Antoine Belaud-Rotureau, Elodie Laharanne, Sandrine Eimer, Kelly Airiau, Hugues Loiseau, Laharanne, Elodie, Loiseau, Hugues, Marie Jeanneteau, Belaud-Rotureau, Marc-Antoine, Eimer, Sandrine, Airiau, Kelly, Jean-Philippe Merlio, Francis Belloc, Merlio, Jean-Philippe, Anne Vital, Nadège Véron   +19 more
core   +1 more source

Serial ctDNA Analysis for Monitoring Molecular Response and Acquired Resistance in Metastatic NSCLC and HR+/HER2‐Negative Breast Cancer: A Real‐World Study

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Circulating tumor DNA (ctDNA) is a promising biomarker for disease monitoring, yet evidence of its clinical utility in routine care remains limited. We evaluated the utility of serial ctDNA monitoring using digital PCR (ddPCR) for detecting acquired resistance (AR) and monitoring response in metastatic non‐small cell lung cancer (NSCLC) and ...
Franciele Hinterholz Knebel, Maurício Fernando Silva Almeida Ribeiro, Rudinei Diogo Marques Linck, Isabela Flauzino Ferreira, Cibele Masotti, Rodrigo Saddi, Karina Perez Sacardo, Felipe Sales Nogueira Amorim Canedo, Leandro Jonata Carvalho Oliveira, Daniele Coelho Duarte, Paula Fontes Asprino, Ernande Xavier dos Santos, Elisângela Monteiro Coser, Dimitrios Kleftogiannis, Louise J. Barber, Marco Gerlinger, João Victor Machado Alessi, Andrea Kazumi Shimada, Fernando Costa Santini, Ciro Eduardo de Souza, Olavo Feher, Gilberto de Castro Junior, Frederico Perego Costa, Max Senna Mano, Artur Katz, Anamaria Aranha Camargo, Fabiana Bettoni   +26 more
wiley   +1 more source

Development of a nanoliposomal formulation of erlotinib for lung cancer and in vitro/in vivo antitumoral evaluation

, 2017
Xiao Zhou, Hui Tao, Kai-Hu Shi Department of Cardiothoracic Surgery, The Second Hospital of Anhui Medical University, Hefei, People’s Republic of China Abstract: The aim of this study was to develop PEGylation liposomes formulations of erlotinib ...
Shi KH, Tao H, Zhou X
core  

A Drug–Drug Interaction Study to Evaluate the Impact of Simvastatin and Itraconazole on Erlotinib Pharmacokinetics in Rats by UPLC-MS/MS

Drug Design, Development and Therapy, 2023
Zaiwen Fan,1 Xiaonan Gao,2 Mingxia Wang,2 Ziqiang Tian1 1Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China; 2Department of Clinical Pharmacology, The Fourth Hospital of Hebei Medical
Fan Z, Gao X, Wang M, Tian Z
doaj